These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248. Treon SP; Hunter ZR; Matous J; Joyce RM; Mannion B; Advani R; Cook D; Songer J; Hill J; Kaden BR; Sharon D; Steiss R; Leleu X; Branagan AR; Badros A Clin Cancer Res; 2007 Jun; 13(11):3320-5. PubMed ID: 17545538 [TBL] [Abstract][Full Text] [Related]
43. Waldenström macroglobulinemia: 2017 update on diagnosis, risk stratification, and management. Gertz MA Am J Hematol; 2017 Feb; 92(2):209-217. PubMed ID: 28094456 [TBL] [Abstract][Full Text] [Related]
44. Histone deacetylase inhibitors demonstrate significant preclinical activity as single agents, and in combination with bortezomib in Waldenström's macroglobulinemia. Sun JY; Xu L; Tseng H; Ciccarelli B; Fulciniti M; Hunter ZR; Maghsoudi K; Hatjiharissi E; Zhou Y; Yang G; Zhu B; Liu X; Gong P; Ioakimidis L; Sheehy P; Patterson CJ; Munshi NC; O'Connor OA; Treon SP Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):152-6. PubMed ID: 21454220 [TBL] [Abstract][Full Text] [Related]
45. Current treatment options for Waldenström macroglobulinemia. Vijay A; Gertz MA Clin Lymphoma Myeloma; 2008 Aug; 8(4):219-29. PubMed ID: 18765309 [TBL] [Abstract][Full Text] [Related]
46. Waldenström's macroglobulinemia. Dimopoulos MA; Anagnostopoulos A Best Pract Res Clin Haematol; 2005; 18(4):747-65. PubMed ID: 16026748 [TBL] [Abstract][Full Text] [Related]
47. Clinicopathologic spectrum of Waldenström's macroglobulinemia: a single center experience. Sajid R; Siddiqui SH; Shaikh U; Adil S Indian J Pathol Microbiol; 2010; 53(3):490-3. PubMed ID: 20699509 [TBL] [Abstract][Full Text] [Related]
48. [Pathology, diagnostics, and treatment of Waldenström's macroglobulinaemia]. Holmström MO Ugeskr Laeger; 2011 Oct; 173(41):2557-60. PubMed ID: 21985832 [TBL] [Abstract][Full Text] [Related]
49. Expression of the human concentrative nucleotide transporter 1 (hCNT1) gene correlates with clinical response in patients affected by Waldenström's Macroglobulinemia (WM) and small lymphocytic lymphoma (SLL) undergoing a combination treatment with 2-chloro-2'-deoxyadenosine (2-CdA) and Rituximab. Rabascio C; Laszlo D; Andreola G; Saronni L; Radice D; Rigacci L; Fabbri A; Frigeri F; Calabrese L; Billio A; Bertolini F; Martinelli G Leuk Res; 2010 Apr; 34(4):454-7. PubMed ID: 19647871 [TBL] [Abstract][Full Text] [Related]
53. The role of serum immunoglobulin free light chain in response and progression in waldenstrom macroglobulinemia. Leleu X; Xie W; Bagshaw M; Banwait R; Leduc R; Roper N; Weller E; Ghobrial IM Clin Cancer Res; 2011 May; 17(9):3013-8. PubMed ID: 21415221 [TBL] [Abstract][Full Text] [Related]
54. A survey on diagnostic methods and treatment strategies used in patients with Waldenström's macroglobulinaemia in The Netherlands. Klodzinska S; Vos JM; Kersten MJ; Wijermans P; Minnema MC Neth J Med; 2013 Mar; 71(2):90-6. PubMed ID: 23462060 [TBL] [Abstract][Full Text] [Related]